Bear Stearns rated Buy Amgen Inc. (NASDAQ: AMGN) on 09/12/2007, when the stock price was $55.86. Since then, Amgen Inc. has gained 178.77% as of 08/27/2015's recent price of $155.72.
If you would have followed this Bear Stearns's recommendation on AMGN, you would have gained 178.76% of your investment in 2906 days.

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

The Bear Stearns Companies Inc. (NYSE: BSC) is the parent company of Bear, Stearns & Co. Inc., a leading global investment banking, securities trading and brokerage firm. Since 1923, we have helped corporations, institutions, governments and individuals reach their financial objectives. Clients have come to rely on the breadth of our expertise, our commitment to client service and our innovative approach to problem-solving. Talented professionals join Bear Stearns because of our unique corporate culture. Based on respect, integrity, meritocracy, innovation and a commitment to philanthropy, these guiding principles serve as blueprint for the way that we do business.

Marked as spam